Evidence map›Paper›PMID 41121746›Full record

ArticlemAbs2025

Bi-functional integrin degraders cause stronger anti-proliferative effects than a blocking antibody by modulating distinct downstream signaling.

Meghan F Monroy, Megan Krumpoch, T Andrew McTeague, Angela Fee, Dooyoung Lee, Zhaohui Sunny Zhou, Fu-Yang Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meghan F MonroyDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.ORCID 0000-0003-0475-1402
Megan KrumpochDepartment of Immunology, Morphic Therapeutic, a Wholly Owned Subsidiary of Eli Lilly and Company, Waltham, MA, USA.
T Andrew McTeagueDepartment of Chemistry, Morphic Therapeutic, a Wholly Owned Subsidiary of Eli Lilly and Company, Waltham, MA, USA.
Angela FeeDepartment of DMPK, Morphic Therapeutic, a Wholly Owned Subsidiary of Eli Lilly and Company, Waltham, MA, USA.
Dooyoung LeeDepartment of DMPK, Morphic Therapeutic, a Wholly Owned Subsidiary of Eli Lilly and Company, Waltham, MA, USA.
Zhaohui Sunny ZhouDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.
Fu-Yang LinDepartment of Molecular and Cell Science, Morphic Therapeutic, a Wholly Owned Subsidiary of Eli Lilly and Company, Waltham, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrins play a critical role in signaling events that regulate cell adhesion, migration, and proliferation, processes that, when dysregulated, contribute to cancer progression. Recently, innovative approaches that target extracellular proteins for degradation have suggested potential in cancer treatment by removing specific cell surface receptors and trafficking them to the lysosome for breakdown. In this context, two integrin degraders were engineered, each exploiting different lysosomal targeting pathways: the asialoglycoprotein receptor (ASGPR) and zinc and ring finger 3 (ZNRF3), respectively. Both degraders use a pan-selective human αv antibody that fully blocks ligand binding, effectively internalizing and degrading αv integrins

Indexed as

Antibodies, MonoclonalIntegrin alphaVNeoplasmsSignal TransductionAnimalsCell Line, TumorCell ProliferationHumansMiceProteolysisXenograft Model Antitumor AssaysAntibodies, MonoclonalIntegrin alphaVAbTACantibody engineeringbi-specific antibodycancer therapeuticslysosomeLYTACPROTABtargeted protein degradationαv integrinαvβ5

Identifiers

PMID41121746
PMCPMC12548079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.